FDA and NIDA supported Adial Pharmaceuticals' clinical development strategy by validating alternative endpoints.
3 reports, 2 independent
Updated Aug 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA and NIDA supported Adial Pharmaceuticals' clinical development strategy by validating alternative endpoints.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA and NIDA validated Adial's clinical strategy using alternative endpoints.1 source
FDA granted Breakthrough Therapy designation and NIDA provided financial support for Ensysce Biosciences.1 source
Keep exploring
The entities involved
- FDA
-
National Institute on Drug Abuse
branch of the National Institutes of Health in the United States
Related events
- FDA approval supports NDA submission in Aurora.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- GlobeNewswireAdial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments U.S. Senate Appropriations Report Furt
- ACCESS NewswireEnsysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy T
- GlobeNewswireAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial”